Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women
Phase II Chemoprevention Trial - Anastrozole in the DCIS and Early Invasive Breast Cancer in Postmenopausal Women
Sponsor: AstraZeneca
Listed as NCT00256217, this PHASE2 trial focuses on DCIS and remains completed. Sponsored by AstraZeneca, it has been updated 13 times since 2004, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
▶ Show 8 earlier versions
-
Jun 2021 — Dec 2022 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Completed → Active Not Recruiting
-
Mar 2019 — Aug 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Feb 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Sep 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Rita Sanghvi, Mehta
For direct contact, visit the study record on ClinicalTrials.gov .